You are here

Justice News

Department of Justice
U.S. Attorney’s Office
District of New Jersey

FOR IMMEDIATE RELEASE
Tuesday, April 9, 2019

Camden County, New Jersey, Man And Philadelphia Man Admit Roles In Conspiracy To Distribute Oxycodone

CAMDEN, N.J. – A Camden County, New Jersey, man and a Philadelphia man today admitted their respective roles in conspiring to distribute oxycodone, U.S. Attorney Craig Carpenito announced.

Daniel Watson, 40, of Bellmawr, New Jersey, and Prussia Hing, 36, of Philadelphia, pleaded guilty before U.S. District Court Judge Jerome B. Simandle in Camden federal court to separate informations charging them each with one count of conspiracy to distribute and possess with intent to distribute oxycodone. Watson and Hing were previously charged in connection with one of the largest national healthcare fraud and opioid enforcement actions ever taken by the U.S. Department of Justice.

According to documents filed in this case and statements made in court:

From December 2017 through June 26, 2018, Watson and Hing conspired with each other and others to distribute unadulterated oxycodone and pressed pills containing oxycodone and hydrocodone, codeine, and methylphenidate. Hing was a source of supply; Watson made eight sales to an undercover officer and a confidential informant, totaling 1,080 oxycodone pills. The final three sales occurred in the vicinity of a Philadelphia hospital, where a conspirator worked as an anesthesiology technologist.

The drug trafficking conspiracy to which Watson and Hing pleaded guilty carries a maximum potential penalty of 20 years in prison and a fine of up to $1 million. Sentencing for both defendants is scheduled for July 17, 2019.

The government is represented by Assistant U.S. Attorneys Diana Vondra Carrig and Christina O. Hud of the U.S. Attorney’s Office Criminal Division in Camden. 

Defense counsel:

Watson: Christopher O’Malley Esq., Assistant Federal Public Defender, Camden

Hing: Gregory Pagano Esq., Philadelphia

Topic(s): 
Drug Trafficking
Prescription Drugs
Component(s): 
Press Release Number: 
19-098
Updated April 9, 2019